EX-99.1 2 a26-08x06jyntq2x26release.htm EXHIBIT-99.1 Document
Exhibit 99.1
logo.jpg

The Joint Corp. Reports Second Quarter 2026 Financial Results
- Consolidated Net Income Increases $560,000 to $653,000;
Adjusted EBITDA From Continuing Operations Increases by $1.4 Million -
- Cash Flow from Operating Activities Rises 152% to $2.2 Million, Driving Free Cash Flow of $1.9 million -
- Delivered on Capital Allocation Priorities with Regional Developer Territory Buybacks and $677,000 in Share Repurchases -

SCOTTSDALE, Ariz., August 6, 2026 - The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, today reported financial results for the second quarter ended June 30, 2026. The following figures represent continuing operations unless otherwise stated.

Second Quarter 2026 Financial Highlights
•Revenues grew to $15.2 million, a 14% increase compared to the second quarter of 2025.
•Reported system-wide sales1 of $180.0 million, a 3.7% decrease compared to the second quarter of 2025.
•Reported comp sales2 of (2.8)%, a 140-basis point improvement compared to the first quarter of 2026.
•Net income from consolidated operations was $653,000, compared to $93,000 in the second quarter of 2025. Net loss from continuing operations was $251,000, compared to a net loss of $1.0 million in the second quarter of 2025.
•Adjusted EBITDA (a non-GAAP metric) from consolidated operations was $3.2 million, in line with $3.2 million in the second quarter of 2025. Adjusted EBITDA from continuing operations was $1.5 million, compared to $88,000 in the second quarter of 2025.
•Cash flow from operating activities improved to $2.2 million compared to $869,000 in the second quarter of 2025, and free cash flow (a non-GAAP metric) was $1.9 million compared to $364,000 in the second quarter of 2025.
•Repurchased 82,000 shares for total consideration of approximately $677,000, at an average of $8.23 per share during the second quarter.
•Completed three regional developer (“RD”) territory buybacks in the second quarter.

Second Quarter 2026 Operating Highlights
•Total clinic count was 941 at June 30, 2026.
◦Opened five clinics, closed seven clinics, and refranchised 29 clinics during the quarter, for a total of 896 franchised clinics and 45 company-owned or managed clinics at June 30, 2026.
•Increased adoption of the Company’s more flexible plan options continues to drive significantly stronger patient retention rate.
1 System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.
2 Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.
1

    



“In the second quarter, we continued to see the benefits of our Joint 2.0 strategy take hold, with our actions to optimize the clinic portfolio, streamline our operating structure, and elevate the patient experience driving improved operating efficiency and strong free cash flow,” said President and Chief Executive Officer of The Joint Corp., Sanjiv Razdan. “We are encouraged with another quarter of revenue growth, as well as the improvement in comp trends compared to the first quarter. We are also seeing the early benefits of our flexible membership options, which contributed to strengthening patient retention. In addition, our national marketing initiative is leveraging consumer research to uncover emerging patient trends, ensuring our offerings align with what patients are seeking from chiropractic care.

“As we enter the second half of 2026, we expect our pure-play franchisor model to drive margin improvement, profitability and continued free cash flow. Our balance sheet remains strong, with $22.2 million in unrestricted cash, which combined with our improving cash generation, positions us to continue to execute on our capital allocation priorities including share repurchases and RD territory buybacks. In addition, we are investing in growth-focused initiatives to deepen patient relationships and improve outcomes across the network. Together, these efforts reinforce our commitment to build sustainable, long-term value for our franchise partners, patients, and stockholders.”

Update on Refranchising Efforts
The Company has substantially completed the refranchising initiative under its Joint 2.0 strategy through three previously announced clinic sale bundles:
•Southern California Bundle: As of August 5, 2026, the buyer has assumed ownership of 32 clinics, with the remaining 13 clinics currently operated by the buyer under Management Service Agreements pending finalization of lease assignments.
•Northern California Bundle: A signed Asset Purchase Agreement is in place for these four clinics.
•Southeast Bundle: As of August 5, 2026, the buyers have assumed ownership of six clinics, with the remaining 15 clinics currently operated by the buyers under Management Service Agreements pending finalization of lease reassignments.

As a result of these refranchising efforts, The Joint Corp. now effectively operates as a capital-light, pure-play franchisor, allowing management to concentrate fully on driving growth through franchise system support, new patient acquisition, and long-term network development.

Financial Results for Second Quarter Ended June 30, 2026 Compared to June 30, 2025
Revenue totaled $15.2 million in the second quarter of 2026, compared to $13.3 million in the second quarter of 2025, reflecting the shift to the Company's pure play franchisor revenue model. Cost of revenues was $2.5 million, down approximately 11% compared to the prior-year period, primarily due to lower RD royalty costs as the Company continues to reacquire RD territories.

Selling and marketing expenses were $4.9 million, an increase of 40% compared to the second quarter of 2025, primarily due to incremental investments in brand awareness and patient acquisition. Depreciation and amortization expenses were $423,000. General and administrative expenses decreased 2% to $7.6 million compared to $7.7 million in the second quarter of 2025, underscoring ongoing operating discipline within the leaner post-refranchising structure.

Consolidated net income was $653,000, compared to $93,000 in the prior-year period. Net loss from continuing operations was $251,000, compared to a net loss of $1.0 million in the second quarter of 2025. Consolidated EPS was $0.05 per diluted share, compared to $0.01 per diluted share in the second quarter of 2025.

Adjusted EBITDA from consolidated operations was $3.2 million, in line with $3.2 million in the second quarter of 2025. Adjusted EBITDA from continuing operations was $1.5 million, compared to $88,000 in the prior-year period.

2

    


Balance Sheet and Stock Repurchase Program
Unrestricted cash was $22.2 million at June 30, 2026, an increase compared to $20.7 million at March 31, 2026. The Company maintains a currently undrawn line of credit with JP Morgan Chase, which provides immediate access to $20 million through August 2029.

During the second quarter of 2026, the Company repurchased approximately 82,000 shares for total consideration of approximately $677,000, at an average price of $8.23 per share. As of June 30, 2026, the Company had $3.8 million remaining under the $12 million stock repurchase program authorized in November 2025.

Financial Results for Six Months Ended June 30, 2026 Compared to June 30, 2025
Revenue was $30.0 million in the first six months of 2026, up 14% compared to $26.3 million in the same period in 2025. Consolidated net income was $2.0 million, compared to $1.1 million in the six months ended June 30, 2025. Net income from continuing operations was $851,000, compared to a net loss of $1.5 million in the six months ended June 30, 2025. Consolidated EPS was $0.14 per diluted share, compared to $0.07 per diluted share in the prior-year period.

Adjusted EBITDA from consolidated operations increased to $6.6 million and Adjusted EBITDA from continuing operations improved to $3.7 million, compared to Adjusted EBITDA from consolidated operations of $6.1 million and Adjusted EBITDA from continuing operations of $134,000 in the six months ended June 30, 2025.

2026 Guidance
The Company reiterated its 2026 financial guidance as originally provided on March 12, 2026, as follows:
•System-wide sales are expected to be between $519 million and $552 million.
•System-wide comp sales for clinics open 13 months or more are expected to be in the range of (3)% to 3%.
•Consolidated Adjusted EBITDA is expected to be in the range of $12.5 million to $13.5 million.
New franchised clinic openings, excluding the impact of refranchised clinics, are now expected to be in the range of 22 to 26. The Company is working with franchise owners to optimize the performance of the existing franchised clinic base. This will include closing underperforming clinics this year, which will result in the overall clinic count at 2026 year end being lower than 2025 year end.

Conference Call
The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, August 6, 2026, after the market close. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing (800) 715-9871 or (646) 307-1963 and using conference ID: 5033381 approximately 15 minutes prior to the start time. The live webcast of the call, including the accompanying slide presentation, can be accessed in the IR events section of The Joint's website at https://ir.thejoint.com/events.

A replay of the webcast will be archived on the Company’s investor relations website for approximately one year. An audio replay of the conference call will be available through Thursday, August 13, 2026, and can be accessed by dialing (855) 669-9658 or (412) 317-0088 and entering conference ID 4782858.

About The Joint Corp. (NASDAQ: JYNT)
The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation’s largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The Company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. Headquartered in Scottsdale and with over 940 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to Franchise Times’ annual “Top 400” and “Fast & Serious” list
3

    


of smartest growing brands. Entrepreneur named The Joint “No. 1 in Chiropractic Services,” and it is regularly ranked on the publication’s “Franchise 500®,” “Fastest-Growing Franchises,” and “Best of the Best” lists, as well as its “Top Franchise for Veterans” and “Top Brands for Multi-Unit Owners” rankings. SUCCESS® named the Company one of the “Top 50 Franchises”. The Joint Chiropractic is an innovative force where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.

Business Structure
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, Washington, and West Virginia, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

Commonly Discussed Performance Metrics
This release includes a presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

Non-GAAP Financial Information
This release also includes a presentation of non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company’s underlying operating performance and operating trends. Free cash flow is presented as a supplemental measure of liquidity. Reconciliation of historical net income/(loss) to EBITDA, Adjusted EBITDA and free cash flow is presented in the tables below. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses (which includes contract termination costs associated with reacquired RD rights), net (gain)/loss on disposition or impairment, stock-based compensation expenses, costs related to restatement filings, restructuring costs, and litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the ordinary course of our business). The company defines free cash flow as net cash provided by (used in) operating activities less capital expenditures. EBITDA, Adjusted EBITDA and free cash flow do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States (“GAAP”). While EBITDA and Adjusted EBITDA are used as measures of financial performance and free cash flow is used as a measure of liquidity, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA, Adjusted EBITDA and free cash flow should be reviewed in conjunction with the company’s financial statements filed with the Securities and Exchange Commission (the “SEC”). Please refer to the reconciliations of non-GAAP financial measures to their GAAP equivalents located at the end of this release. This release includes forward-looking guidance for certain non-GAAP financial measures, including Adjusted EBITDA. These measures will differ from net income (loss), determined in accordance with GAAP, in ways similar to those described in the reconciliations at the end of this release. We are not able to provide, without unreasonable effort, guidance for net income (loss), determined in accordance with GAAP, or a reconciliation of guidance for Adjusted EBITDA to the most directly comparable GAAP measure because the company is not able to predict with reasonable certainty the amount or nature of all items that will be included in net income (loss).

Forward-Looking Statements
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations
4

    


of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Words such as "anticipates," "believes," "continues," "estimates," "expects," "goal," "objective," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. Specific forward-looking statements made in this press release include, among others, our belief that in the second quarter, we continued to see the benefits of our Joint 2.0 strategy take hold, with our actions to optimize the clinic portfolio, streamline our operating structure, and elevate the patient experience driving improved operating efficiency and strong free cash flow; our belief that we are encouraged with another quarter of revenue growth, as well as the strengthening of comp trends as we exited the second quarter; our belief that we are seeing the early benefits of our flexible membership options, which contributed to strengthening patient retention; our belief that our national marketing initiative is leveraging consumer research to uncover emerging patient trends, ensuring our offerings align with what patients are seeking from chiropractic care; our expectation that as we enter the second half of 2026, our pure-play franchisor model will drive margin improvement, profitability and continued free cash flow; our belief that our balance sheet remains strong, with $22.2 million in unrestricted cash, which combined with our improving cash generation, positions us to continue to execute on our capital allocation priorities including share repurchases and RD territory buybacks; our plan to invest in growth-focused initiatives to deepen patient relationships and improve outcomes across the network and our belief that, together, these efforts reinforce our commitment to build sustainable, long-term value for our franchise partners, patients, and stockholders; and our reiterated 2026 guidance for system-wide sales, system-wide comp sales, consolidated Adjusted EBITDA, new franchised clinic openings, and overall clinic count. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, leading to increased labor costs and interest rates, as well as changes to import tariffs and increased gas prices, may lead to reduced discretionary spending, all of which may negatively impact our business; our failure to profitably operate company-owned or managed clinics; our failure to refranchise as planned; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and other factors described in our filings with the SEC, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 13, 2026 and subsequent filings with the SEC. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.
Investor Contact:
Richard Land, Alliance Advisors IR, thejointinvestor@allianceadvisors.com (212)-838-3777

– Financial Tables Follow –

5

    


THE JOINT CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30,
2026		December 31,
2025
ASSETS(unaudited)
Current assets:
Cash and cash equivalents$22,157,203 $23,601,810 
Restricted cash846,359 700,058 
Accounts receivable, net2,407,080 2,849,864 
Deferred franchise and regional development costs, current portion895,572 945,933 
Prepaid expenses and other current assets2,735,610 1,744,556 
Discontinued operations current assets ($1.0 million attributable to VIEs)14,760,981 22,246,318 
Total current assets43,802,805 52,088,539 
Property and equipment, net2,823,232 3,159,226 
Operating lease right-of-use asset1,454,886 1,572,173 
Deferred franchise and regional development costs, net of current portion3,259,579 3,827,129 
Deposits and other assets286,847 319,460 
Total assets$51,627,349 $60,966,527 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$1,097,862 $1,588,665 
Accrued expenses1,855,708 1,501,838 
Co-op funds liability846,359 700,058 
Payroll liabilities2,139,102 4,055,752 
Operating lease liability, current portion340,885 194,179 
Deferred franchise fee revenue, current portion2,698,531 2,519,018 
Upfront regional developer fees, current portion178,540 277,394 
Other current liabilities641,515 611,231 
Discontinued operations current liabilities ($3.2 million and $6.1 million attributable to VIEs, respectively)14,180,239 21,368,446 
Total current liabilities23,978,741 32,816,581 
Operating lease liability, net of current portion1,696,293 1,815,527 
Deferred franchise fee revenue, net of current portion9,861,323 10,899,271 
Upfront regional developer fees, net of current portion215,683 355,556 
Total liabilities35,752,040 45,886,935 
Commitments and contingencies
Stockholders' equity:
Series A preferred stock, $0.001 par value; 50,000 shares authorized, zero shares issued and outstanding, respectively— — 
Common stock, $0.001 par value; 20,000,000 shares authorized, 15,755,965 shares issued and 14,199,592 shares outstanding and 15,471,715 shares issued and 14,142,626 shares outstanding, respectively15,755 15,471 
Additional paid-in capital52,766,531 52,026,407 
Treasury stock 1,556,373 shares and 1,329,089 shares, at cost, respectively(14,088,928)(12,192,081)
Accumulated deficit(22,843,049)(24,795,205)
Total The Joint Corp. stockholders' equity15,850,309 15,054,592 
Non-controlling Interest25,000 25,000 
Total equity15,875,309 15,079,592 
Total liabilities and stockholders' equity$51,627,349 $60,966,527 
6

    


THE JOINT CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Revenues:
Royalty fees$8,327,549 $8,133,121 $16,359,838 $16,204,107 
Franchise fees750,587 768,100 1,895,655 1,596,619 
Advertising fund revenue3,715,837 2,332,695 7,362,920 4,640,197 
Software fees1,547,331 1,481,661 3,082,232 2,943,628 
Other revenues840,610 554,692 1,301,502 963,309 
Total revenues15,181,914 13,270,270 30,002,147 26,347,860 
Cost of revenues:
Franchise and regional development cost of revenues2,070,339 2,350,613 4,340,097 4,901,848 
IT cost of revenues406,911 421,994 859,808 842,885 
Total cost of revenues2,477,250 2,772,607 5,199,905 5,744,733 
Selling and marketing expenses4,886,151 3,483,844 8,603,055 6,988,994 
Depreciation and amortization422,861 402,295 819,554 764,225 
General and administrative expenses7,556,216 7,745,251 14,641,202 14,660,196 
Total selling, general and administrative expenses
12,865,228 11,631,390 24,063,811 22,413,415 
Net loss on disposition or impairment208,093 4,440 233,420 6,413 
(Loss) income from continuing operations(368,657)(1,138,167)505,011 (1,816,701)
Other income, net126,438 159,922 366,673 345,839 
(Loss) income before income tax expense(242,219)(978,245)871,684 (1,470,862)
Income tax expense9,108 11,390 20,220 24,794 
Net (loss) income from continuing operations(251,327)(989,635)851,464 (1,495,656)
Discontinued operations:
Income from discontinued operations before income tax expense901,789 1,183,199 1,280,502 2,760,428 
Income tax (benefit) expense from discontinued operations(2,559)100,201 179,810 203,613 
Net income from discontinued operations904,348 1,082,998 1,100,692 2,556,815 
Net income$653,021 $93,363 $1,952,156 $1,061,159 
Net (loss) income from continuing operations per common share:
Basic$(0.01)$(0.06)$0.06 $(0.10)
Diluted$(0.01)$(0.06)$0.06 $(0.10)
Net income from discontinued operations per common share:
Basic$0.06 $0.07 $0.08 $0.17 
Diluted$0.06 $0.07 $0.08 $0.17 
Net income per common share:
Basic$0.05 $0.01 $0.14 $0.07 
Diluted$0.05 $0.01 $0.14 $0.07 
Basic weighted average shares14,244,929 15,326,317 14,213,195 15,256,755 
Diluted weighted average shares14,246,993 15,400,408 14,216,232 15,328,198 

7

    


THE JOINT CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
Six Months Ended
June 30,
20262025
Cash flows from operating activities:
Net income$1,952,156 $1,061,159 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization829,001 807,730 
Net loss on disposition or impairment1,427,651 2,892,265 
Net franchise fees recognized upon termination of franchise agreements(395,159)(174,285)
Provision for credit losses122,823 — 
Stock-based compensation expense703,180 624,929 
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable454,019 1,558,183 
Prepaid expenses and other current assets(833,199)(1,743,981)
Deferred franchise costs408,499 183,839 
Deposits and other assets34,849 18,332 
Accounts payable(607,825)(91,075)
Accrued expenses629,565 (3,408,504)
Payroll liabilities(2,560,203)(1,446,598)
Operating leases(1,615,535)(2,719,624)
Deferred revenue(625,793)(508,565)
Upfront regional developer fees(238,727)(145,605)
Other liabilities1,030,748 259,795 
Net cash provided by (used in) operating activities716,050 (2,832,005)
Cash flows from investing activities:
Proceeds from sale of clinics1,160,284 7,778,287 
Purchase of property and equipment(490,858)(836,545)
Net cash provided by investing activities669,426 6,941,742 
Cash flows from financing activities:
Payments of finance lease obligation— (4,354)
Purchases of treasury stock under employee stock plans(74,983)(8,440)
Purchases of common stock under share repurchase programs(1,821,864)— 
Proceeds from exercise of stock options37,228 905,976 
Net cash (used in) provided by financing activities(1,859,619)893,182 
(Decrease) increase in cash, cash equivalents and restricted cash(474,143)5,002,919 
Cash, cash equivalents and restricted cash, beginning of period24,301,868 25,996,436 
Cash, cash equivalents and restricted cash, end of period$23,827,725 $30,999,355 
Reconciliation of cash, cash equivalents and restricted cash:June 30, 2026June 30, 2025
Cash and cash equivalents$22,157,203 $29,811,667 
Restricted cash1,670,522 1,187,688 
Cash, cash equivalents and restricted cash, end of period$23,827,725 $30,999,355 
8

    


THE JOINT CORP.
CONSOLIDATED RECONCILIATION FROM GAAP TO NON-GAAP
(unaudited)

Three Months Ended June 30,
20262025
From Continuing OperationsFrom Discontinued OperationsNet OperationsFrom Continuing OperationsFrom Discontinued OperationsNet Operations
Non-GAAP Financial Data:
Net (loss) income$(251,327)$904,348 $653,021 $(989,635)$1,082,998 $93,363 
Net interest income(126,439)— (126,439)(159,922)— (159,922)
Depreciation and amortization expense422,861 1,690 424,551 402,295 17,120 419,415 
Income tax expense (benefit)9,108 (2,559)6,549 11,390 100,201 111,591 
EBITDA54,203 903,479 957,682 (735,872)1,200,319 464,447 
Stock-based compensation expense423,180 — 423,180 330,988 — 330,988 
Acquisition-related expenses332,005 — 332,005 — — — 
Net loss on disposition or impairment208,093 816,466 1,024,559 4,440 1,752,494 1,756,934 
Restructuring costs113,451 (24,422)89,029 488,493 198,331 686,824 
Litigation expenses321,693 12,005 333,698 — — — 
Adjusted EBITDA$1,452,625 $1,707,528 $3,160,153 $88,049 $3,151,144 $3,239,193 

Six Months Ended June 30,
20262025
From Continuing OperationsFrom Discontinued OperationsNet OperationsFrom Continuing OperationsFrom Discontinued OperationsNet Operations
Non-GAAP Financial Data:
Net income (loss)$851,464 $1,100,692 $1,952,156 $(1,495,656)$2,556,815 $1,061,159 
Net interest (income) expense(368,188)— (368,188)(345,839)238 (345,601)
Depreciation and amortization expense819,554 9,447 829,001 764,225 43,505 807,730 
Income tax expense20,220 179,810 200,030 24,794 203,613 228,407 
EBITDA1,323,050 1,289,949 2,612,999 (1,052,476)2,804,171 1,751,695 
Stock-based compensation expense703,180 — 703,180 624,929 — 624,929 
Acquisition-related expenses332,005 — 332,005 — — — 
Net loss on disposition or impairment233,420 1,194,230 1,427,650 6,413 2,885,852 2,892,265 
Restructuring costs740,338 56,784 797,122 555,577 269,715 825,292 
Litigation expenses346,694 421,775 768,469 — — — 
Adjusted EBITDA$3,678,687$2,962,738$6,641,425$134,443$5,959,738$6,094,181















9

    


THE JOINT CORP.
RECONCILIATION OF OPERATING ACTIVITIES CASH FLOWS TO FREE CASH FLOW(1)
(unaudited)

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Cash flows provided by (used in) operating activities$2,192,220 $868,649 $716,050 $(2,832,005)
Purchase of property and equipment(256,258)(505,040)(490,858)(836,545)
Free cash flow$1,935,962 $363,609 $225,192 $(3,668,550)
(1) Free cash flow represents cash flows provided by (used in) operating activities less capital expenditures.
10